leadf
logo-loader
viewMaxCyte Inc

MaxCyte signs clinical and commercial licensing deal APEIRON Biologics

Chief executive Doug Doerfler said: "This agreement represents an important achievement for MaxCyte, and highlights the value of our next-generation technology platform to companies across the globe seeking to unlock the potential of their engineered cell therapy programmes"

MaxCyte Inc -

MaxCyte Inc (LON:MXCT) has signed a clinical and commercial licensing deal with a company developing a gene silencing drug for solid tumours.

Under the agreement, APEIRON Biologics will be allowed to use the AIM-listed group’s Flow Electroporation technology and ExPERT platform to advance APN401, a siRNA-based cell therapy.

In return, MaxCyte will receive “undisclosed development and approval milestones and sales-based payments in addition to other licensing fees”.

In a statement, MaxCyte chief executive Doug Doerfler said: "This agreement represents an important achievement for MaxCyte, and highlights the value of our next-generation technology platform to companies across the globe seeking to unlock the potential of their engineered cell therapy programmes."

Quick facts: MaxCyte Inc

Price: 410 GBX

AIM:MXCT
Market: AIM
Market Cap: £316.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

2 min read